NCT05531734

Brief Summary

To develop an easy-to-use measurement tool for monitoring fatigue and alertness, particularly in sleep-deprived subjects.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 14, 2022

Completed
3 months until next milestone

First Posted

Study publicly available on registry

September 8, 2022

Completed
7 months until next milestone

Study Start

First participant enrolled

March 22, 2023

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2025

Completed
Last Updated

April 27, 2025

Status Verified

April 1, 2025

Enrollment Period

2.4 years

First QC Date

June 14, 2022

Last Update Submit

April 25, 2025

Conditions

Keywords

Measurement toolEEG datasleep deprivationattentionelectroencephalogram

Outcome Measures

Primary Outcomes (1)

  • EEG data collected by head phone like EEG electrodes developed by NaoX Technologies

    Demonstrate that the NaoX head phone like EEG electrodes detects sleep deprivation in medical residents performing medical shifts. The primary endpoint is the detection of a significant decrease in Coefficient Alpha Attenuation (CAA) between the pre- and post-sleep deprivation measurements. The data analysis will be blinded to the measurement.

    through study completion, an average of 12 hours

Secondary Outcomes (2)

  • Demonstrate a link between the Alpha Attenuation Coefficient (AAC) measured by NaoX head phone like EEG electrodes and the vigilance tests

    through study completion, an average of 12 hours

  • Demonstrate a link between the Alpha Attenuation Coefficient (AAC) measured by the NaoX head phone like EEG electrodes tool and the state of fatigue experienced

    through study completion, an average of 12 hours

Study Arms (1)

volunteers

EXPERIMENTAL

Health volunteers

Device: NaoX Intra-Auricular Device (IAD) monitoring EEG dataBehavioral: Simple psychometric tests

Interventions

Intrauaricular measurement tool developed by NaoX Technology to retrieve EEG type data.

volunteers

Associated with simple and self-managed psychometric tests.

volunteers

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy volunteers.
  • Male, female.
  • Medical residents.
  • Aged between 24 and 34 years.
  • Doing emergency, intensive care or "inside" shifts.
  • Working in a health institution.
  • No history of epilepsy.
  • No background treatment that could have an impact on the EEG (electroencephalogram) data (type: benzodiazepines, anti-epileptics).
  • No significant change in background treatment during the study, if any.
  • Affiliation to the social security system.
  • Informed volunteer who has signed a consent form.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pediatric Intensive Care Unit, Raymond Poincaré Hospital, APHP

Garches, 92380, France

RECRUITING

MeSH Terms

Conditions

FatigueSleep Deprivation

Condition Hierarchy (Ancestors)

Signs and SymptomsPathological Conditions, Signs and SymptomsDyssomniasSleep Wake DisordersNervous System DiseasesNeurologic ManifestationsMental Disorders

Study Officials

  • Jean BERGOUNIOUX, MD, PhD

    Pediatric Intensive Care Unit, Raymond Poincaré Hospital, APHP

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 14, 2022

First Posted

September 8, 2022

Study Start

March 22, 2023

Primary Completion

September 1, 2025

Study Completion

September 1, 2025

Last Updated

April 27, 2025

Record last verified: 2025-04

Data Sharing

IPD Sharing
Will not share

Locations